Themis in the News

Themis-CEPI partnership

BioCentury

Funding Outbreak Prevention

more
BioWorld

CEPI betting up to $37.5M on Themis for Lassa, MERS vaccines

more
Endpoints News

As killer virus outbreaks hit unprecedented levels, nonprofit hands $37.5M to Themis to tackle Lassa/MERS vaccines

more
Fierce Pharma

World's first Lassa vaccine, developed by Themis, nears human testing: CEO

more
Le Monde.fr

La fièvre de Lassa, maladie proche d’Ebola, se répand au Nigeria

more
Nature

Health officials push for vaccine against neglected tropical virus

more
Scrip

Themis Bioscience Reaps Bill Gates' Backed CEPI Funding For Lassa Fever And MERS Vaccines

more
STAT

Global health coalition inks agreement to develop vaccines for MERS, Lassa fever

more
transkript

CEPI kürt Themis zu Premierenpartner

more
thepharmaletter

$37.5 million investment in Austrian vaccines developer Themis Bioscience

more

Themis- Series C Announcement

Fierce Pharma

Themis nabs €10M series C for chikungunya, Zika push

more
Finsmes

Themis Raises €10M in Series C Financing

more
Labiotech.eu

Austrian Vaccines Biotech Closes €10M Series C to Stop Global Outbreaks

more
VC-Magazin.de

10 Mio. EUR für Themis Bioscience

more